Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

Hepatitis B vaccine birth dose down 2% in children under 2 years old, CDC immunization report finds

Immunization rates are declining in infants and toddlers 24 months and younger, according to the most recent National Immunization Survey-Child report from the Centers for Disease Control and Prevention.

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Adding IMNN-001, a DNA-mediated immunotherapy, to standard-of-care treatment improved median overall survival by 14.7 months in patients with newly diagnosed advanced ovarian cancer, final clinical data from the OVATION 2 study shows.

April 03, 2026

Vol.52 No.13

Drugs & Targets

FDA approves relacorilant + nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

FDA approved relacorilant (Lifyorli), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

March 27, 2026

Vol.52 No.12

Podcast

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Last week’s issue of The Cancer Letter was dominated by one event: the meeting of the National Cancer Advisory Board, the group of experts which advises and assists the NCI director on the activities of the National Cancer Program.

March 25, 2026

Cancer Policy

The reconstitution of ACIP and changes to CDC’s childhood vaccine schedule were likely illegal, judge rules

Judge Brian E. Murphy, of the U.S. District Court for the District of Massachusetts, temporarily blocked a series of recent changes to the CDC vaccine schedule.

Positive topline results announced from phase I study of Lymphir + pembrolizumab in r/r gynecologic cancers

Citius Oncology announced positive topline results from a completed investigator‑initiated phase I clinical trial conducted by University of Pittsburgh investigators. This study evaluated the direct T-regulatory cell depletion activity of Lymphir (denileukin diftitox‑cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (Keytruda) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies.

March 13, 2026

Vol.52 No.10

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

YOU MAY BE INTERESTED IN

Hepatitis B vaccine birth dose down 2% in children under 2 years old, CDC immunization report finds

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

FDA approves relacorilant + nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

The reconstitution of ACIP and changes to CDC’s childhood vaccine schedule were likely illegal, judge rules

Positive topline results announced from phase I study of Lymphir + pembrolizumab in r/r gynecologic cancers

Renew today!

Subscriber content

Never miss an issue!

Login